Pancreatic Cancer Research

ResearcherThe University of SydneyActive in the last 2 years

Sumit Sahni

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2900-8845; OpenAlex author ID A5075875051. Sources: OpenAlex.

Their work

Papers
25 (first author 2, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
29
Papers, trials and grants by year

2020: 6 papers · 2021: 5 papers · 2022: 3 papers · 2023: 3 papers · 2024: 3 papers · 2025: 5 papers

Papers 25

  1. FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival. Co-author DOI 10.1002/cam4.70500↗
  2. Overcoming therapy resistance in pancreatic cancer: challenges and emerging strategies. Last author DOI 10.1016/j.addr.2025.115647↗
  3. Promising biomarker panel to monitor therapeutic efficacy of neoadjuvant chemotherapy in pancreatic cancer patients. Last author DOI 10.1111/eci.14341↗
  4. Total lesion glycolysis is a promising predictor of chemo-response in pancreatic cancer patients treated with neoadjuvant chemotherapy prior to surgery. Last author DOI 10.1111/eci.70046↗
  5. Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification. Co-author DOI 10.1158/2767-9764.crc-25-0229↗
  6. Gene Expression Profiling of Pancreatic Ductal Adenocarcinoma Arising From Intraductal Papillary Mucinous Neoplasms of the Pancreas. Co-author DOI 10.1002/cam4.70499↗
  7. Novel serum protein biomarker panel for early diagnosis of pancreatic cancer. Last author DOI 10.1002/ijc.34928↗
  8. Serum and tissue metallome of pancreatic ductal adenocarcinoma. Last author DOI 10.1111/cas.16124↗
  9. Heterogeneous tumor microenvironment in pancreatic ductal adenocarcinoma: An emerging role of single-cell analysis. Last author DOI 10.1002/cam4.6407↗
  10. The role of diagnostic, prognostic, and predictive biomarkers in the management of early pancreatic cancer. Co-author DOI 10.1007/s00432-023-05149-4↗
  11. The Prognostic and Predictive Role of the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Lymphocyte-to-Monocyte Ratio (LMR) as B… Co-author DOI 10.3390/jcm12051989↗
  12. Targeting Wnt/tenascin C-mediated cross talk between pancreatic cancer cells and stellate cells via activation of the metastasis suppressor NDRG1. Co-author DOI 10.1016/j.jbc.2022.101608↗
  13. Autophagy: A Key Player in Pancreatic Cancer Progression and a Potential Drug Target. Last author DOI 10.3390/cancers14143528↗
  14. The Right Treatment Strategy for the Right Patient: A Biomarker-Driven Approach to Neoadjuvant vs. Surgery-First Management of Resectable and Borderline Resect… Co-author DOI 10.3390/cancers14153620↗
  15. A unique urinary metabolomic signature for the detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33368↗
  16. Data independent acquisition of plasma biomarkers of response to neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.jprot.2020.103998↗
  17. Breaking the cycle: Targeting of NDRG1 to inhibit bi-directional oncogenic cross-talk between pancreatic cancer and stroma. Co-author DOI 10.1096/fj.202002279r↗
  18. A Critical Assessment of Postneoadjuvant Therapy Pancreatic Cancer Regression Grading Schemes With a Proposal for a Novel Approach. Co-author DOI 10.1097/pas.0000000000001601↗
  19. Optimal Upfront Treatment in Surgically Resectable Pancreatic Cancer Candidates: A High-Volume Center Retrospective Analysis. Co-author DOI 10.3390/jcm10122700↗
  20. Regulation of autophagy and apoptosis by Dp44mT-mediated activation of AMPK in pancreatic cancer cells. First author DOI 10.1016/j.bbadis.2019.165657↗
  21. NDRG1 suppresses basal and hypoxia-induced autophagy at both the initiation and degradation stages and sensitizes pancreatic cancer cells to lysosomal membrane… Co-author DOI 10.1016/j.bbagen.2020.129625↗
  22. PSMD11, PTPRM and PTPRB as novel biomarkers of pancreatic cancer progression. Co-author DOI 10.1016/j.bbagen.2020.129682↗
  23. Mechanically stressed cancer microenvironment: Role in pancreatic cancer progression. Co-author DOI 10.1016/j.bbcan.2020.188418↗
  24. Tissue biomarker panel as a surrogate marker for squamous subtype of pancreatic cancer. Co-author DOI 10.1016/j.ejso.2020.02.001↗
  25. Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy? Last author DOI 10.3390/cancers12051341↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jaswinder Singh Samra · 20 shared papers, 2020–2025 · strength 3.55
  2. Anubhav Mittal · 20 shared papers, 2020–2025 · strength 3.55
  3. Anthony James Gill · 15 shared papers, 2020–2025 · strength 2.77
  4. Nick Pavlakis · 10 shared papers, 2020–2025 · strength 1.62
  5. Sarah Maloney · 8 shared papers, 2020–2025 · strength 1.41
  6. Sooin Byeon · 6 shared papers, 2023–2025 · strength 1.38
  7. Josef Gillson · 7 shared papers, 2020–2025 · strength 1.23
  8. Stephen John Clarke · 6 shared papers, 2021–2025 · strength 0.96
  9. Angela S. Y. Chou · 4 shared papers, 2021–2025 · strength 0.72
  10. Taymin du Toit‐Thompson · 3 shared papers, 2023–2025 · strength 0.69
  11. Christopher Bahdah Nahm · 4 shared papers, 2020–2025 · strength 0.61
  12. Des Raymond Richardson · 4 shared papers, 2020–2022 · strength 0.56
  13. Mark P. Molloy · 3 shared papers, 2020–2024 · strength 0.53
  14. Emily K. Colvin · 3 shared papers, 2022–2023 · strength 0.49
  15. Malinda Itchins · 3 shared papers, 2021–2023 · strength 0.42
  16. David Lok Hang Chan · 2 shared papers, 2023–2025 · strength 0.39
  17. Bekesho Geleta · 2 shared papers, 2021–2022 · strength 0.29
  18. Žaklina Kovačević · 2 shared papers, 2021–2022 · strength 0.29
  19. Minoti Vivek Apte · 2 shared papers, 2021–2022 · strength 0.29
  20. Yogambha Ramaswamy · 2 shared papers, 2020 · strength 0.25
  21. Nathalie B. Rasko · 1 shared paper, 2025 · strength 0.25
  22. William A. Ziaziaris · 1 shared paper, 2024 · strength 0.24
  23. Matthew B. O’Rourke · 1 shared paper, 2021 · strength 0.17
  24. Sukriti Krishan · 1 shared paper, 2020 · strength 0.15
  25. Matthew Kyle Hadden · 1 shared paper, 2020 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.